Role of MRD Negativity Rates in Treatment Decision Making

Opinion
Video

Three medical oncologists explore the influence of MRD negativity rates on treatment decisions and discover the ideal patient profile for quadruplet regimen.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Recent Videos
      “If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
      JNJ-5322 Shows Efficacy in Later-Line Multiple Myeloma
      Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
      MRD Recurrence Shown to Precede Biochemical Relapse in Multiple Myeloma
      The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
      JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma
      The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
      Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
      4 experts are featured in this series.
      Real World Experience of CAR-T in MM Patients
      4 experts are featured in this series.
      Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
      4 experts are featured in this series.
      Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
      4 experts are featured in this series.
      Future Perspectives: What’s Next in NDMM?
      4 experts are featured in this series.
      Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
      4 experts are featured in this series.
      Jackson’s Journey with High Risk R/R MM
      Related Content
      A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.

      Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma

      Tim Cortese
      July 13th 2025
      Article

      A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.

      ASCT Shows No Significant MRD Difference vs Isa-KRd in Multiple Myeloma

      Russ Conroy
      July 9th 2025
      Article

      Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

      Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

      Roman Fabbricatore
      July 2nd 2025
      Article

      The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

      Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

      Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

      Roman Fabbricatore
      July 2nd 2025
      Article

      Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.